DBV Technologies S.A.
Close on Oct 19, 2026
- Market cap
- $3.89B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 28, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 16, 2026 | During market hours | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 30, 2026 | During market hours | – | $-0.11 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 29, 2025 | During market hours | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 29, 2025 | During market hours | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 30, 2025 | During market hours | – | $-0.26 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 24, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 22, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 30, 2024 | During market hours | $1.20M | $-0.34 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 7, 2024 | During market hours | – | – | – |
Press releases
Announcements DBV Technologies filed with the SEC
Châtillon, France, July 16, 2026
Results of operations · EX-99.1 to Form 8-K
Châtillon, France, June 29, 2026
Other events · EX-99.1 to Form 8-K
Châtillon, France, April 30, 2026
Results of operations · EX-99.1 to Form 8-K
DBV Technologies Reports Full Year 2025 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting
Other events · EX-99.1 to Form 8-K
DBV Technologies Announces 166.7 Million in Gross Proceeds Following the Full Exercise
Other events · EX-99.1 to Form 8-K
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
DBV Technologies Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
DBV Technologies Announces Resignation of Board Member
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Châtillon, France, September 5, 2025
Other events · EX-99.1 to Form 8-K
DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers
Other events · EX-99.1 to Form 8-K
DBV Technologies Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
DBV Technologies Announces Financing of up to $306.9 Million (284.5
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for Biologics License Application (BLA) for
Results of operations · Other events · EX-99.1 to Form 8-K
DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3
Regulation FD disclosure · EX-99.1 to Form 8-K
Châtillon, France, December 11 th , 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
DBV Technologies Announces Plan to Implement ADS Ratio Change
Regulation FD disclosure · EX-99.1 to Form 8-K
Châtillon, France, November 6, 2024
Results of operations · EX-99.1 to Form 8-K
DBV Announces Positive Regulatory Updates for the Viaskin ® Peanut
Results of operations · Other events · EX-99.1 to Form 8-K
DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial
Other events · EX-99.1 to Form 8-K
Châtillon, France, July 30, 2024
Results of operations · EX-99.1 to Form 8-K
Châtillon, France, May 31, 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
DBV Technologies Announces Plan to Implement ADS Ratio Change
Regulation FD disclosure · EX-99.1 to Form 8-K
Montrouge, France, May 7, 2024
Results of operations · EX-99.1 to Form 8-K
DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal
Regulation FD disclosure · EX-99.1 to Form 8-K
Montrouge, France, March 7, 2024
Results of operations · EX-99.1 to Form 8-K
Montrouge, France, November 9, 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
DBV Technologies Receives Requested Feedback from FDA on
Agreement terminated · Results of operations · EX-99.1 to Form 8-K
Montrouge, France, October 16, 2023
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second
Results of operations · EX-99.1 to Form 8-K
DBV Technologies Announces New England
Regulation FD disclosure · EX-99.1 to Form 8-K
DBV Technologies Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA
Results of operations · Other events · EX-99.1 to Form 8-K
DBV Technologies Announces First Patient
Other events · EX-99.1 to Form 8-K
DBV Technologies Reports Full Year 2022 Financial Results and Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial
Other events · EX-99.1 to Form 8-K